首页> 外文OA文献 >Langzeituntersuchung zur In-Stent-Restenose eines neuen biodegradierbaren, wirkstoffbeladenen, intravaskulären Polylaktidstents nach Implantation in porcine Koronararterien
【2h】

Langzeituntersuchung zur In-Stent-Restenose eines neuen biodegradierbaren, wirkstoffbeladenen, intravaskulären Polylaktidstents nach Implantation in porcine Koronararterien

机译:新型可生物降解,载药性血管内聚乳酸支架植入猪冠状动脉后的支架内再狭窄的长期研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The aim of this study was to assess technical feasibility, biocompatibility, and impact on coronary stenosis of a new biodegradable paclitaxel-loaded polylactide stent. Due to high rates of instent restenosis and permanent nature of metal stent implants, synthetic polymers have been proposed as surrogate materials for stents and local delivery systems for drugs. Paclitaxel was shown to inhibit vascular smooth muscle cell proliferation and migration. A novel biodegradable double-helical stent was manufac-tured using controlled expansion of saturated polymers (CESP) for the moulding of a bioresorbable poly(D,L)-lactic acid (PDLLA). A modified balloon catheter for stent deployment was developed according to the mechanical stent properties. Twelve paclitaxel-loaded (170 microg) polylactide stents, 12 unloaded polylactide stents, and 12 316L bare metal stents were deployed in porcine coronary arteries of 36 animals. Six pigs of each group were sacrificed after 3 weeks and 3 months, respectively, for every setting. Drug release kinetics as well as histomorphometrical and histopathologi-cal analyses were performed. A slow paclitaxel release kinetic for more than 2 months and therapeutic tissue concentrations were demonstrated. Coronary stenosis after implantation of paclitaxel-loaded stents (30+/-5% or 49+/-4%) was significantly inhibited compared to unloaded PDLLA stents (65+/-10%, P=0.021 or 71+/-4%, P=0.004) and metal stents (53+/-6% or 68+/-8%, P=0.029 and P=0.020) after 3 weeks or 3 months. Early complete endothelialisation was shown. Nevertheless, a local inflammatory response to the polylactide as a result of the polymer resorption process was observed. This novel polylactide stent showed sufficient mechanic stability, and by incorporation of paclitaxel, a significant potential to reduce restenosis development after vascular intervention was seen.
机译:这项研究的目的是评估一种新型的可生物降解的紫杉醇负载的聚乳酸支架的技术可行性,生物相容性及其对冠状动脉狭窄的影响。由于支架内再狭窄的高发生率和金属支架植入物的永久性,已提出使用合成聚合物作为支架的替代材料和药物的局部递送系统。紫杉醇被证明抑制血管平滑肌细胞增殖和迁移。使用饱和聚合物的可控膨胀(CESP)制造一种新型的可生物降解的双螺旋支架,用于模制可生物吸收的聚(D,L)-乳酸(PDLLA)。根据支架的机械性能,开发了一种用于支架部署的改进型气囊导管。在36只动物的猪冠状动脉中部署了十二个装载紫杉醇(170微克)的聚丙交酯支架,十二个未装载的聚丙交酯支架和12个316L裸金属支架。每组分别在3周和3个月后处死每组六头猪。进行了药物释放动力学以及组织形态计量学和组织病理学分析。紫杉醇缓慢释放动力学超过2个月,并证明了治疗组织的浓度。与未装载PDLLA支架(65 +/- 10%,P = 0.021或71 +/- 4%)相比,装载紫杉醇支架(30 +/- 5%或49 +/- 4%)植入后的冠状动脉狭窄得到了显着抑制。 ,P = 0.004)和金属支架(53 +/- 6%或68 +/- 8%,P = 0.029和P = 0.020)在3周或3个月后。显示了早期完全内皮化。然而,由于聚合物的吸收过程,观察到了对聚丙交酯的局部炎症反应。这种新型的聚丙交酯支架显示出足够的机械稳定性,并且通过掺入紫杉醇,在减少血管干预后,可以显着减少再狭窄的发展。

著录项

  • 作者

    Stein Andreas;

  • 作者单位
  • 年度 2006
  • 总页数
  • 原文格式 PDF
  • 正文语种 ger
  • 中图分类

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号